CN1683407A - Synthetic process for alkaline phosphatase marked free thyroid hormone - Google Patents
Synthetic process for alkaline phosphatase marked free thyroid hormone Download PDFInfo
- Publication number
- CN1683407A CN1683407A CN 200410097170 CN200410097170A CN1683407A CN 1683407 A CN1683407 A CN 1683407A CN 200410097170 CN200410097170 CN 200410097170 CN 200410097170 A CN200410097170 A CN 200410097170A CN 1683407 A CN1683407 A CN 1683407A
- Authority
- CN
- China
- Prior art keywords
- alkaline phosphatase
- polymer
- thyroid hormone
- synthesis technique
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020004774 Alkaline Phosphatase Proteins 0.000 title claims abstract description 76
- 102000002260 Alkaline Phosphatase Human genes 0.000 title claims abstract description 76
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 title claims abstract description 50
- 239000005495 thyroid hormone Substances 0.000 title claims abstract description 44
- 229940036555 thyroid hormone Drugs 0.000 title claims abstract description 44
- 238000000034 method Methods 0.000 title claims abstract description 39
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 19
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 19
- 239000000126 substance Substances 0.000 claims abstract description 13
- 229920000642 polymer Polymers 0.000 claims description 40
- 238000006243 chemical reaction Methods 0.000 claims description 39
- 239000007822 coupling agent Substances 0.000 claims description 28
- 238000000502 dialysis Methods 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 13
- 238000013016 damping Methods 0.000 claims description 12
- 239000012530 fluid Substances 0.000 claims description 12
- 239000002504 physiological saline solution Substances 0.000 claims description 12
- 229920005654 Sephadex Polymers 0.000 claims description 11
- 239000012507 Sephadex™ Substances 0.000 claims description 11
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 9
- 238000010521 absorption reaction Methods 0.000 claims description 8
- 238000005516 engineering process Methods 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 6
- 238000005192 partition Methods 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 3
- 108010013043 Acetylesterase Proteins 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 238000004458 analytical method Methods 0.000 abstract description 4
- 238000004020 luminiscence type Methods 0.000 abstract description 3
- 239000003550 marker Substances 0.000 abstract description 3
- 239000000427 antigen Substances 0.000 abstract description 2
- 102000036639 antigens Human genes 0.000 abstract description 2
- 108091007433 antigens Proteins 0.000 abstract description 2
- 230000008878 coupling Effects 0.000 abstract description 2
- 238000010168 coupling process Methods 0.000 abstract description 2
- 238000005859 coupling reaction Methods 0.000 abstract description 2
- 230000001900 immune effect Effects 0.000 abstract 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 6
- 229940035722 triiodothyronine Drugs 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 229940034208 thyroxine Drugs 0.000 description 4
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000003556 assay Methods 0.000 description 2
- 238000006872 enzymatic polymerization reaction Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 241000473945 Theria <moth genus> Species 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention discloses synthesis process of alkaline phosphatase marked free thyroid hormone. The structure of alkaline phosphatase is reformed for coupling with thyroid hormone to prepare marker antigen. The present invention has simple technological process and low cost, and solves the difficult problem of preparing alkaline phosphatase marker as the key component for free thyroid hormone detecting kit in the immunological analysis of chemical luminescence.
Description
Technical field
The present invention relates to a kind of synthesis technique that is applied to the alkaline phosphatase marked free thyroid hormone in the chemiluminescence immunoassay technology.
Background technology
Triiodothyronine comprises thyroxine (Thyroxine, T4) and triiodothyronine (Triiodothyronine, T3), their overwhelming majority in blood plasma exist with the protein binding form, 0.2% the ratio of only being no more than is with free thyroxine (Free Thyroxine, FT4) and free triiodothyronine (Free Triiodothyronine, FT3) form exists, but have only the free form that physiologically active is just arranged, thereby free triiodothyronine (FT3) and free thyroid hormone (FT4) are the important indicators of diagnosis thyroid disease.
Radioimmunoassay (RIA) commonly used at present is to use
125I designate similar thing realizes that its synthesis technique complexity, validity period weak point have certain pollution to environment, and the factor that influences detected result is more.The research of chemiluminescence immunoassay technology (CLIA) has obtained breakthrough over surplus in the of nearly 10 year, no matter be sensitivity, easy fast and multinomial technical indicator such as level of automation all meet or exceed the RIA level, particularly the stability of marker and free from environmental pollution be that RIA is unrivaled.The equal import of domestic big-and-middle-sized hospital at present CLIA automatical analysis system.But instrument and reagent cost an arm and a leg, and particularly the marking process of test kit neutral and alkali Phosphoric acid esterase (Apase) is the highly confidential proprietary technology of external producer, up to now, do not see the report of this technology both at home and abroad as yet.
Summary of the invention
The object of the present invention is to provide the simple and easy to do synthesis technique with alkaline phosphatase polymer marked free thyroid hormone of a kind of technology, its synthetic alkaline phosphatase polymer-free thyroid hormone binding substances is the key ingredient that chemiluminescence immune assay detects the free thyroid hormone test kit.
The inventor is through lot of experiments, according to the molecular structure of free thyroid hormone and the physicochemical property of alkaline phosphatase, structure to alkaline phosphatase is transformed, and with the free thyroid hormone coupling with the preparation labelled antigen, develop a kind of simple and easy to do synthesis technique.
Specifically, the synthesis technique of alkaline phosphatase marked free thyroid hormone of the present invention comprises: alkaline phosphatase polymer and free thyroid hormone reaction are generated alkaline phosphatase polymer-free thyroid hormone binding substances.
Wherein, the reaction of described alkaline phosphatase polymer and free thyroid hormone is linked reaction.
Described linked reaction is alkaline phosphatase polymer and the reaction of free thyroid hormone in the presence of coupling agent, after for example alkaline phosphatase polymer and free thyroid hormone mix, drips coupling agent and react in the solution of pH 6～8.
In described linked reaction, the consumption of each reactant and coupling agent can be the conventional or known consumption in this area.The consumption of alkaline phosphatase polymer and free thyroid hormone also can be the alkaline phosphatase polymer: free thyroid hormone is the ratio of 1nmol: 2～10nmol.The coupling agent consumption can be according to the alkaline phosphatase polymer of the every 1nmol coupling agent with 20～50 μ L.Reaction medium can be conventional or known medium, for example physiological saline of pH 6～8 of this area.
Described alkaline phosphatase polymer and free thyroid hormone mix, and can be to prepare the polymeric normal saline solution of alkaline phosphatase earlier, add free thyroid hormone again, mix; Otherwise also can.
Described linked reaction can be to get the alkaline phosphatase polymer to pack in the dialysis tubing, with normal saline dialysis 6～8 hours, liquid is changed 1 time in the centre, get alkaline phosphatase polymer 2nmol and add physiological saline to 1000 μ L, add 5～20nmol free thyroid hormone, 100 μ L, thorough mixing dropwise adds 40～100 μ L coupling agents, room temperature reaction 2～4 hours in mixed solution.
Described coupling agent can be conventional or known coupling agent, for example glutaraldehyde of this area.
Synthesis technique of the present invention also comprises separated product from reaction system, described from reaction system the method for separated product can be this area routine or separation known method, for example adopt sephadex column partition method separated product.
The condition of described employing sephadex column partition method separated product can be that this area is conventional or known, for example reaction solution is added in the SephadexG100 post after the damping fluid balance use pH 6～8 in advance, damping fluid drip washing with pH 6～8, flow velocity 0.1～0.4ml/min, collect leacheate, select the leacheate of second absorption peak of ultraviolet 280nm, be required product.
Described alkaline phosphatase polymer is with the polymer of alkaline phosphatase by 4～6 molecules of linked reaction generation, also can adopt the commercially available prod.
Described alkaline phosphatase polymer can be by the conventional or known method preparation in this area.Described alkaline phosphatase polymer can be prepared as follows: the ratio that coupling agent is added 20～50 μ L coupling agents in every milligram of alkaline phosphatase dropwise adds in pH6～8 alkaline phosphatase enzyme solution reacts, and then reaction solution is isolated the alkaline phosphatase polymer with the sephadex column partition method from reaction system.
Preferred, described alkaline phosphatase polymer adopts the preparation of following method: get alkaline phosphatase through normal saline dialysis after 18～24 hours, the ratio that adds 20～50 μ L coupling agents in every milligram of alkaline phosphatase dropwise adds, behind the room temperature reaction 1～2 hour, with 4 ℃ of dialysis of physiological saline 18～24 hours, liquid is changed 1～3 time in the centre, then reaction solution is added in the Sephadex G100 post after the damping fluid balance use pH 6～8 in advance, damping fluid drip washing with pH 6～8, flow velocity 0.1～0.4ml/min, collect leacheate, middle portion and the molecular weight of getting the absorption peak of ultraviolet 280nm are the alkaline phosphatase polymer liquid of 30～600,000 Da.
Described coupling agent is the conventional or known coupling agent in this area, is preferably glutaraldehyde.
The technical scheme of alkaline phosphatase polymer marked free thyroid hormone synthesis technique the best of the present invention may further comprise the steps:
(1) the polymeric preparation of alkaline phosphatase
Get alkaline phosphatase through normal saline dialysis 18～20 hours, add physiological saline to 5mg/mL, the ratio that adds 20～50 μ L coupling agents in every milligram of alkaline phosphatase dropwise adds coupling agent, behind the room temperature reaction 1～2 hour, reaction solution is packed in the dialysis tubing of diameter 8mm, with 4 ℃ of dialysis of physiological saline 18～20 hours, liquid is changed 2 times in the centre, the reaction solution adding is used in pH 7.0 phosphate buffer solns (PBS) the equilibrated Sephadex G100 post in advance, with pH 7.0 PBS drip washing, flow velocity 0.2ml/min, leacheate is in charge of collection, middle portion and the molecular weight of getting the absorption peak of ultraviolet 280nm are the alkaline phosphatase polymer liquid of 30～600,000 Da, add the equivalent glycerol, and 4 ℃ of preservations are standby.
(2) preparation of alkaline phosphatase polymer-free thyroid hormone
(1) the alkaline phosphatase polymer of getting above-mentioned preparation is packed in the dialysis tubing, with normal saline dialysis 6～8 hours, liquid is changed 1 time in the centre, get alkaline phosphatase polymer 2nmol and add physiological saline to 1000 μ L, add 5～20nmol free thyroid hormone, 100 μ L, thorough mixing dropwise adds 40～100 μ L coupling agents, room temperature reaction 2～4 hours in mixed solution;
(2) reaction solution is added in the SephadexG100 post use in advance after the pH 7.5 Tris-HCl damping fluid balances, with pH 7.5 Tris-HCl damping fluid drip washing, flow velocity 0.2ml/min collects leacheate, selects the leacheate of second absorption peak peak value of ultraviolet 280nm;
(3) leacheate of selecting is changed in the clean vial, add MgCl respectively
2And ZnCl
2Making its concentration is 2mmol/L and 0.2mmol/L, adds NaN again
3And bovine serum albumin (BSA) to make its concentration be 0.1% and 10mg/mL, treat that fully the dissolving back adds the equivalent glycerol, fully packing behind the mixing, 4 ℃ of preservations.
In the above-mentioned processing step, described coupling agent preferably is glutaraldehyde.Described reaction system is preferably the physiological saline of pH 7.5.
Described alkaline phosphatase can adopt the commercially available prod, for example the product P 5521 of sigma company.The reagent of other uses such as coupling agent and instrument also are the commercially available prod.
The inventive method has solved and has perplexed in the chemiluminescence immune assay field difficult problem that the key ingredient alkali phosphatase enzyme mark thing that detects the free thyroid hormone test kit is difficult to prepare always.It is simple and easy to do, with low cost to adopt the inventive method to prepare alkaline phosphatase polymer-free thyroid hormone binding substances, and alkaline phosphatase links to each other with target molecule by linking agent, and its loss of activity is little.
Embodiment
Below will the invention will be further described by embodiment, these descriptions are not that content of the present invention is done further to limit.One skilled in the art will understand that to be equal to replacement to what technical characterictic of the present invention was done, or corresponding the improvement, still belong within protection scope of the present invention.
Embodiment 1: the polymeric preparation of alkaline phosphatase
(1) gets alkaline phosphatase 5mg (sigma product P 5521) through normal saline dialysis 20 hours, add physiological saline, dropwise add 150 μ L coupling agent glutaraldehyde to 1.0ml, behind the room temperature reaction 1 hour, pack in the diameter 8mm dialysis tubing, with 4 ℃ of dialysis of physiological saline 18 hours, liquid was changed 2 times in the centre.The reaction solution adding is used in 20mmol/L pH 7.0 PBS equilibrated 1.0 * 35cm SephadexG100 post in advance, with 20mmol/L pH 7.0 PBS drip washing, flow velocity 0.2ml/min, every 0.5mL collect 1 pipe, collect about 20 pipes altogether, detect each pipe with ultraviolet 280nm, the absorption peak of 280nm is divided into 3 parts, on ultraviolet spectrophotometer, surveys the OD value respectively, calculate 3 parts protein mass separately, every part adds equivalent AR level glycerol, 4 ℃ of preservations.
(2) the learn from else's experience enzymatic polymerization thing liquid of each 200 μ g of isolating 3 parts of post compares the enzymatic polymerization thing molecular weight of 3 parts of mensuration with standard molecular weight albumen at AmershamBiosciences SE400 standard vertical gel electrophoresis system.Record molar mass average＞600,000 Da of first part, about 30～600,000 Da of the molecular weight of second section, the molecular weight of third part is＜30 ten thousand Da approximately.Its polymkeric substance is respectively 6～8 polymers, 4～6 polymers and 2～4 polymers, and with the liquid reservation of second section, being can be for the alkaline phosphatase polymkeric substance of mark.
Embodiment 2-3: the polymeric preparation of alkaline phosphatase
Prepare the alkaline phosphatase polymer according to the method for implementing 1, just adding the coupling agent glutaraldehyde is 100 μ L, 250 μ L, and the room temperature reaction time is 2 hours, and rate of flow in rinse is 0.1ml/min, 0.4ml/min.
Embodiment 4: the preparation of alkaline phosphatase polymer-free thyroid hormone
(1) gets in embodiment 1 gained alkaline phosphatase polymer 1mg (the being 2nmol) dialysis tubing of packing into, to normal saline dialysis 6 hours, liquid is changed once in the centre, add physiological saline to 1000 μ L, add 10nmol free thyroid hormone 100 μ L, thorough mixing dropwise adds 60 μ L coupling agent glutaraldehyde, room temperature reaction 2.5 hours in mixed solution;
(2) reaction solution is added in the 1.0 * 35cm Sephadex G100 post use in advance after the 0.1mol/L pH 7.5 Tris-HCl damping fluid balances, with 0.1mol/LpH 7.5 Tris-HCl damping fluid drip washing, flow velocity 0.2ml/min, collect the every 0.5mL1 pipe of leacheate, select the peak value leacheate of second absorption peak of ultraviolet 280nm;
(3) leacheate of collecting is changed in the clean vial, add MgCl respectively
2And ZnCl
2Making its concentration is 2mmol/L and 0.2mmol/L, adds NaN again
3And bovine serum albumin (BSA) makes its concentration be respectively 0.1% and 10mg/mL, and fully the dissolving back adds the equivalent glycerol, and fully packing 100 μ L/ prop up behind the mixing, and 4 ℃ of preservations are put in sealing.
Embodiment 5-7: the preparation of alkaline phosphatase polymer-free thyroid hormone
Prepare alkaline phosphatase polymer-free thyroid hormone according to the method for implementing 4, just add 5nmol, 15nmol, 20nmol free thyroid hormone, adding the coupling agent glutaraldehyde is 40 μ L, 80 μ L, 100 μ L, room temperature reaction 2 hours, 3 hours, 4 hours.
Embodiment 8: alkaline phosphatase polymer-free thyroid hormone binding substances application test
With embodiment 4 synthetic alkaline phosphatase polymers-free thyroid hormone binding substances (Apase-FT3, Apase-FT4) and the Apase-FT3 and the Apase-FT4 binding substances of gondola ADALTIS company be applied to respectively compare experiment in FT3 and the FT4 chemical luminescence immune analysis reagent box, comparing result sees Table 1:
The mass parameter comparing result of table 1 test kit
| Mass parameter | ?????????????FT3 | ???????????????FT4 | ||
| Product of the present invention | ADALTIS company | Product of the present invention | ADALTIS company | |
| Sensitivity | ??0.17pmol/L | ????0.15pmol/L | ????0.08pmol/L | ????0.06pmol/L |
| CV in crowd | ??10.2％ | ????11.3％ | ????9.1％ | ????8.5％ |
| The rate of recovery | ??95.6％ | ????96.3％ | ????102.6％ | ????97.0％ |
| Linear r value | ??0.9976 | ????0.9984 | ????0.9981 | ????0.9985 |
Respectively 216 routine serum samples are detected simultaneously, the result is as shown in table 2 below:
Table 2 serum sample detected result
| Project | Normal group (example) | The low group of first (example) | Hyperthyroid group (example) | Total coincidence rate | |||
| Product of the present invention | ADALTIS company | Product of the present invention | ADALTIS company | Product of the present invention | ADALTIS company | ||
| ??FT3 | ??115 | 117 | ??14 | 11 | ??13 | 14 | ??95.8％ |
| ??FT4 | ??117 | 116 | ??15 | 16 | ??13 | 13 | ??98.6％ |
From above contrast and experiment as can be seen: this technology synthetic alkaline phosphatase polymer-free thyroid hormone binding substances and external like product are applied to the chemical luminescence immune analysis reagent box, be that the mass parameter of test kit or the result who detects clinical serum sample are very approaching, reach excellent results, alkaline phosphatase marked free thyroid hormone new synthetic process of the present invention has fine suitability and advance.
Claims (10)
1, a kind of synthesis technique of alkaline phosphatase marked free thyroid hormone is characterized in that this technology comprises: alkaline phosphatase polymer and free thyroid hormone generate alkaline phosphatase polymer-free thyroid hormone binding substances by linked reaction.
2, synthesis technique according to claim 1 is characterized in that described linked reaction is after alkaline phosphatase polymer and free thyroid hormone mix, and drips coupling agent and reacts in the solution of pH6～8.
3, synthesis technique according to claim 2, the ratio that it is characterized in that described linked reaction neutral and alkali Phosphoric acid esterase polymer and free thyroid hormone is the alkaline phosphatase polymer: free thyroid hormone is 1nmol: 2～10nmol, and the coupling agent consumption is that the alkaline phosphatase polymer of every nmol is with 20～50 μ L.
4, synthesis technique according to claim 1, it is characterized in that described linked reaction packs in the dialysis tubing for getting the alkaline phosphatase polymer, with normal saline dialysis 6～8 hours, liquid is changed 1 time in the centre, get alkaline phosphatase polymer 2nmol and add physiological saline to 1000 μ L, add 5～20nmol free thyroid hormone, 100 μ L, thorough mixing, in mixed solution, dropwise add 40～100 μ L glutaraldehyde, room temperature reaction 2～4 hours.
5, synthesis technique according to claim 1 is characterized in that also comprising with sephadex column partition method separated product from reaction system.
6, synthesis technique according to claim 5, it is characterized in that described sephadex column partition method separated product is that reaction solution is added in the Sephadex G100 post after the damping fluid balance use pH6～8 in advance, damping fluid drip washing with pH6～8, flow velocity 0.1～0.4ml/min, collect leacheate, selecting the leacheate of second absorption peak of ultraviolet 280nm is required product.
7,, it is characterized in that described alkaline phosphatase polymer is the polymer that generates 4～6 molecules with alkaline phosphatase by linked reaction according to the described arbitrary synthesis technique of claim 1-4.
8, synthesis technique according to claim 7, it is characterized in that described alkaline phosphatase polymer adopts following method to make: the ratio that coupling agent is added 20～50 μ L coupling agents in every milligram of alkaline phosphatase adds in the alkaline phosphatase enzyme solution of pH6～8 reacts, and then reaction solution is isolated the alkaline phosphatase polymer with the sephadex column partition method from reaction system.
9, synthesis technique according to claim 7, it is characterized in that described alkaline phosphatase polymer adopts following method to make: get alkaline phosphatase through normal saline dialysis 18～24 hours, the ratio that adds 20～50 μ L coupling agents in every milligram of alkaline phosphatase dropwise adds glutaraldehyde, behind the room temperature reaction 1～2 hour, with 4 ℃ of dialysis of physiological saline 18～24 hours, liquid is changed 1～3 time in the centre, then reaction solution is added in the Sephadex G100 post after the damping fluid balance use pH6～8 in advance, damping fluid drip washing with pH6～8, flow velocity 0.1～0.4ml/min, collect leacheate, middle portion and the molecular weight of getting the absorption peak of ultraviolet 280nm are the alkaline phosphatase polymer liquid of 30～600,000 Da.
10, according to claim 3,8 arbitrary described synthesis technique, it is characterized in that described coupling agent is a glutaraldehyde.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410097170 CN1285611C (en) | 2003-12-17 | 2004-12-13 | Synthetic process for alkaline phosphatase marked free thyroid hormone |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200310123659 | 2003-12-17 | ||
| CN200310123659.8 | 2003-12-17 | ||
| CN 200410097170 CN1285611C (en) | 2003-12-17 | 2004-12-13 | Synthetic process for alkaline phosphatase marked free thyroid hormone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1683407A true CN1683407A (en) | 2005-10-19 |
| CN1285611C CN1285611C (en) | 2006-11-22 |
Family
ID=35262929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410097170 Active CN1285611C (en) | 2003-12-17 | 2004-12-13 | Synthetic process for alkaline phosphatase marked free thyroid hormone |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1285611C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8476050B2 (en) | 2010-06-04 | 2013-07-02 | Shenzhen Mindray Bio-Medical Electronics Co., Ltd. | Conjugate preparation methods and related kit |
| US8753858B2 (en) | 2009-12-31 | 2014-06-17 | Shenzhen Mindray Bio-Medical Electronics Co., Ltd. | Reagents and processes for stabilizing alkaline phosphatase or conjugates thereof |
| US8940512B2 (en) | 2010-06-04 | 2015-01-27 | Shenzhen Mindray Bio-Medical Electronics Co., Ltd. | Processes for synthesizing alkaline phosphatase conjugates |
| CN113214380A (en) * | 2021-05-06 | 2021-08-06 | 三诺生物传感股份有限公司 | Preparation method of alkaline phosphatase-labeled thyroxine |
-
2004
- 2004-12-13 CN CN 200410097170 patent/CN1285611C/en active Active
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8753858B2 (en) | 2009-12-31 | 2014-06-17 | Shenzhen Mindray Bio-Medical Electronics Co., Ltd. | Reagents and processes for stabilizing alkaline phosphatase or conjugates thereof |
| US8476050B2 (en) | 2010-06-04 | 2013-07-02 | Shenzhen Mindray Bio-Medical Electronics Co., Ltd. | Conjugate preparation methods and related kit |
| US8940512B2 (en) | 2010-06-04 | 2015-01-27 | Shenzhen Mindray Bio-Medical Electronics Co., Ltd. | Processes for synthesizing alkaline phosphatase conjugates |
| CN113214380A (en) * | 2021-05-06 | 2021-08-06 | 三诺生物传感股份有限公司 | Preparation method of alkaline phosphatase-labeled thyroxine |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1285611C (en) | 2006-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Smith et al. | Colorimetric method for the assay of heparin content in immobilized heparin preparations | |
| CN102565405A (en) | Method for immunological detection by combining acridinium ester labeling technology with general magnetic particles | |
| CN101368966A (en) | Chemical luminescence immune assay determination reagent kit for gastrin releasing peptide precursor | |
| CN105467122A (en) | Kit and method for detection of thyroid peroxidase antibody | |
| CN103063851A (en) | Free triiodothyronine nanometer magnetic particle chemiluminescence assay kit and preparation method thereof and detection method thereof | |
| CN101639481A (en) | Magnetic particle chemiluminescence immunoassay kit of free thyroxine | |
| CN103063845A (en) | Nanometer magnetic particle chemiluminiscence kit, preparation method and detection method of hepatitis B virus surface-antibody | |
| CN110196334A (en) | Thrombomodulin chemiluminescence immunoassay immue quantitative detection reagent box and preparation method thereof | |
| CN1285611C (en) | Synthetic process for alkaline phosphatase marked free thyroid hormone | |
| CN107860914A (en) | A kind of anti-mitochondrial antibody IgG detection kit and its detection method | |
| CN103675299A (en) | Kit and method for detecting concentration of fibronectin in urine | |
| CN109342718A (en) | A kind of magnetic microparticle chemiluminescence detection method | |
| JPS6145776B2 (en) | Specif combination analysis using prosthetic group as labelling component* reagent and composition for same* test kit* and ligand | |
| CN1404577A (en) | Immunological assay reagents and assay method | |
| Grant et al. | A sensitive method for detection of sulfamethazine and N 4-acetylsulfamethazine residues in environmental samples using solid phase immunoextraction coupled with MALDI-TOF MS | |
| CN110702828A (en) | Method for determining four arsenic morphological concentrations in whole blood or red blood cells by HPLC-HG-AFS method | |
| EP2028250A1 (en) | Luminescence enhancer | |
| US4391795A (en) | Assay for free thyroid hormone | |
| USRE32696E (en) | Enzymatic immunological method for determination of antigens and antibodies | |
| EP0460097A4 (en) | Method and diagnostic test kit for detection of anti-cardiolipin | |
| Ikariyama et al. | Solid-phase luminescent catalyst immunoassay for human serum albumin with hemin as labeling catalyst | |
| Narinesingh et al. | Flow injection analysis of serum urea using urease covalently immobilized on 2-fluoro-1-methylpyridinium salt-activated fractogel and fluorescence detection | |
| Miyauchi | Direct Measurement of High-Density Lipoprotein Cholesterol in Serum with Polyethylene Glycol-Mod ified Enzymes and Sulfated a-Cyclodextrin | |
| Gebauer et al. | Immunoassay studies using adenosine deaminase enzyme with Potentiometric rate measurement | |
| CN1209615C (en) | Visual fluorescence immunoassay method for determining biological active substance |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: BEIJING CHEMCLIN BIOTECH CO., LTD. Free format text: FORMER OWNER: BEIJING CHEMCLIN BIOTECH CO., LTD.; APPLICANT Effective date: 20060421 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20060421 Address after: 100094 Beijing city Haidian District industrial base in Yongfeng Feng Xian Road No. 7 North Park Applicant after: Kemei Dongya Biological Technology Co., Ltd., Beijing Address before: 100012 Beijing Chaoyang District Andingmen Dayangfang No. 6 Applicant before: Kemei Dongya Biological Technology Co., Ltd., Beijing Co-applicant before: Beimian-Dongya Inst. of Biotechnology, Beijing |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100094 NO.7, FENGXIAN MIDDLE ROAD, YONGFENG INDUSTRIAL BASE, HAIDIAN DISTRICT, BEIJING TO: 100094 NO.7, FENGXIAN MIDDLE ROAD, YONGFENG BASE, HAIDIAN DISTRICT, BEIJING |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20100531 Address after: 100094 Beijing city Haidian District Yongfeng base Feng Xian Road No. 7 North Park Patentee after: Beijing Kemei Biological Technology Co., Ltd. Address before: 100094 Beijing city Haidian District industrial base in Yongfeng Feng Xian Road No. 7 North Park Patentee before: Kemei Dongya Biological Technology Co., Ltd., Beijing |
|
| CP03 | Change of name, title or address |
Address after: 100094 Beijing Haidian District Yongfeng Base Fengxianzhong Road 7 Beike Modern Manufacturing Park Incubation Building Patentee after: Kemei Diagnostic Technology Co., Ltd Address before: 100094 Beijing city Haidian District Yongfeng base Feng Xian Road No. 7 North Park Patentee before: BEIJING CHEMCLIN BIOTECH Co.,Ltd. |
|
| CP03 | Change of name, title or address |